Fatty acid supplement gets results in joint health study

A recent clinical trial on Celadrin, a nutritional supplement made of a combination of cetylated fatty acids, show that it promotes joint health.

US nutraceutical company Imagenetix claims that results from a clinical trial on its product Celadrin, a natural nutritional supplement made of a combination of cetylated fatty acids, show that it promotes joint health.

The clinical trial is published in the current issue of the Journal of Rheumatology.In the double-blind, multi-centre, placebo-controlled trial, researchers examined the impact of a 68-day oral administration of Celadrin on 64 participants who were experiencing joint and mobility problems.

The placebo group and the Celadrin group were evaluated at the beginning, at 30 days, and at 68 days. Among other measurements, evaluations included physician assessment, knee range of motion and the Lequesne algofunctional index.

The company reports that after 68 days participants who consumed Celadrin showed healthy joint mobility, flexibility and function compared to those given the placebo.

Participants' responses to the Lequesne index indicated a significant shift towards functional improvement for the Celadrin group compared to the participants given the placebo.

Data from the study also indicated that Celadrin not only promoted joint flexibility, but also supported and promoted the ability to walk long distances. Imagenetix stressed that participants in the study exhibited no side effects.

"Our goal is to make Celadrin available to the millions of people who can benefit from it," said Bill Spencer, president of the San Diego-based Imagenetix which develops private-label and co-brand nutritional and skin care products.

"Celadrin is unique. It does not contain Glucosamine, Chondroitin, MSM or SAMe. Additionally, unlike many competitive products, with over 90,000,000 Celadrin pills distributed to date, we have no reported adverse side effects. Safe and effective products, available at a reasonable cost, and backed by solid scientific research continue to be a consumer priority."

Celadrin cream is currently being subjected to a clinical trial and Celadrin cream with menthol is currently being marketed as an OTC pain-relieving product.